Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor Presentation

2 Sep 2022 10:02

RNS Number : 1044Y
Byotrol PLC
02 September 2022
 

 

 

 

Byotrol plc

("Byotrol" or the "Company")

Investor Presentation

 

Byotrol plc (AIM: BYOT), the developer of anti-microbial technologies, is pleased to announce that David Traynor, CEO, Chris Sedwell, CFO, and Vivan Pinto, CGO, will provide a live presentation relating to Final Results 2022 via the Investor Meet Company platform on 15th September 2022 at 11:00am BST.

 

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet Byotrol plc via:

 

https://www.investormeetcompany.com/byotrol-plc/register-investor

 

Investors who already follow Byotrol on the Investor Meet Company platform will automatically be invited.

 

 

For further information, visit www.byotrolplc.com, follow on twitter @byotrol, or contact

 

Byotrol plc

David Traynor - Chief Executive Officer

Chris Sedwell - Chief Financial Officer 01925 742 000

 

finnCap Limited (Nominated Adviser and Broker)

Geoff Nash/James Thompson - Corporate Finance

Richard Chambers - ECM 020 7220 0500

 

Flagstaff Strategic and Investor Communications 020 7129 1474

Tim Thomson/Andrea Seymour/Fergus Melon byotrol@flagstaffcomms.com

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading infection prevention and control company, operating globally in the animal health, human health, facilities management, and consumer sectors.

 

Byotrol develops unique antimicrobial technologies for use on surfaces, skin and instruments, which it then commercialises through market-leading distribution partners in each sector.

 

Byotrol's antimicrobial technologies can be licensed for use in leading brands, to significantly improve their product claims, while reassuring consumers and end-users of their efficacy and quality.

 

Founded in 2005, the Company develops technologies and products with the aim of providing easier, safer and cleaner lives for everyone. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBKBBQFBKKOCK
Date   Source Headline
5th Sep 20077:01 amRNSDirector/PDMR Shareholding
4th Sep 20077:00 amRNSDirectorate Change
31st Aug 200710:07 amRNSTotal Voting Rights
16th Aug 20078:41 amRNSAIM RULE 26 INFORMATION
6th Aug 20072:49 pmRNSAdditional Listing
1st Aug 20078:21 amRNSTotal Voting Rights
1st Aug 20077:01 amRNSDirector/PDMR Shareholding
30th Jul 20071:04 pmRNSAGM Statement
30th Jul 20077:01 amRNSJoint Venture
20th Jun 20077:01 amRNSAnnual Report and Accounts
8th Jun 20077:00 amRNSAdditional Listing
4th Jun 20077:00 amRNSNEW GLOBAL CONTRACT
4th May 20077:01 amBUSBYOTROL plc • HEALTHCARE PRODUCT LAUNCH
18th Apr 20077:45 amRNSTrading Statement
30th Mar 20079:24 amRNSTotal Voting Rights
22nd Mar 20072:47 pmRNSHolding(s) in Company
19th Mar 20079:56 amRNSHolding(s) in Company
19th Mar 20079:52 amRNSHolding(s) in Company
19th Mar 20079:51 amRNSHolding(s) in Company
19th Mar 20079:49 amRNSHolding(s) in Company
13th Mar 20073:28 pmRNSAdditional Listing
28th Feb 20071:04 pmRNSTotal Voting Rights
23rd Feb 20077:01 amRNSAdditional Listing
21st Feb 20077:01 amRNSDirector/PDMR Shareholding
8th Feb 20073:54 pmRNSAdditional Listing
5th Feb 20072:52 pmRNSHolding(s) in Company
19th Jan 20072:30 pmRNSTotal Voting Rights
12th Jan 20073:07 pmRNSIssue of Equity
14th Dec 20065:00 pmRNSTotal Voting Rights
11th Dec 20067:00 amRNSInterim Results
27th Nov 20069:32 amRNSBoard Appointment
14th Nov 20067:03 amRNSSynergy Healthcare Agreement
1st Nov 20067:01 amRNSIssue of Equity
26th Oct 20061:12 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 20061:02 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200612:28 pmBUSByotrol Plc Distribution Agreements Signed for Healthcare Sector
26th Oct 200610:24 amRNSDistribution Agreements
16th Oct 20067:01 amBUSByotrol Plc: Result of Byotrol Use in Hospital
18th Sep 200610:56 amBUSREPEAT: Byotrol Plc: Chinese Patent Granted and Customer Orders Shipped
18th Sep 200610:30 amBUSByotrol Plc: Chinese Patent Granted and Customer Orders Shipped
11th Sep 20067:01 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.